Morria Biopharmaceuticals Plc Names Dr. Gur Roshwalb as CEO
3/5/2013 7:52:33 AM
More...
|
Morria Biopharmaceuticals Plc Announces Quotation for Trading on the OTC Bulletin Board
2/19/2013 9:04:23 AM
More...
|
Morria Biopharmaceuticals Plc Announces Full Time Appointment of Alan Harris, M.D., Ph.D., as Chief Medical Officer
1/23/2013 9:14:08 AM
More...
|
Morria Biopharmaceuticals Plc Appoints Charles Serhan Ph.D. to Scientific Advisory Board
7/18/2012 8:39:30 AM
More...
|
Morria Biopharmaceuticals Plc Appoints Alan Harris, M.D., Ph.D., as Chief Medical Officer
7/2/2012 10:26:13 AM
More...
|
Morria Biopharmaceuticals Plc Selects SCYNEXIS, Inc. to Support CMC Activities for MRX-4, a Novel Anti-Inflammatory Drug for Allergic Rhinitis
2/16/2012 8:41:39 AM
More...
|
Morria Biopharmaceuticals Plc Announces Positive Safety, Tolerability and Preliminary Efficacy Results for MRX-4 Phase II Study in Allergic Rhinitis at the EAACI Congress
6/15/2010 7:12:26 AM
More...
|
Promising Safety, Tolerability and Efficacy Results from Morria Biopharmaceuticals Plc' MRX-4 Phase II Study in Allergic Rhinitis to be Presented at the upcoming EAACI Congress
6/3/2010 9:46:29 AM
More...
|
Morria Biopharmaceuticals Plc Announces Initiation of Its Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug
4/21/2010 9:21:55 AM
More...
|
Morria Biopharmaceuticals Plc Obtains Institutional Review Board Clearance to Conduct Phase II Study in Contact Dermatitis Patients Using MRX6, a Novel Topical Anti-Inflammatory Drug
8/25/2009 9:57:43 AM
More...
|
|